Various interferon (IFN)-inducible transmembrane (IFITM) proteins for COVID-19, is there a role for the combination of mycophenolic acid and interferon?

Biochimie. 2020 Oct:177:50-52. doi: 10.1016/j.biochi.2020.08.006. Epub 2020 Aug 14.

Abstract

Various interferon (IFN)-inducible transmembrane (IFITM) proteins are known to be expressed in human tissues though only IFITM 1-3 are inducible by IFN. Numerous studies have shown that activation of IFITM3 could suppress infection by influenza and coronaviruses such as the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). In view of the potential application of IFITM proteins' induction to target SARS-CoV-2 infection that causes COVID-19, this article layout insights into the known antiviral mechanisms and therapeutic agents related to IFITM. Blocking viral entry through various mechanisms and the potential application of the FDA approved immunosuppressant agent, mycophenolic acid, as inducer of IFITM3 are among those discussed.

MeSH terms

  • Animals
  • Betacoronavirus / drug effects*
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / metabolism
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Interferons / pharmacology*
  • Membrane Proteins / drug effects*
  • Membrane Proteins / immunology
  • Mycophenolic Acid / pharmacology*
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / metabolism
  • RNA-Binding Proteins / drug effects*
  • RNA-Binding Proteins / immunology
  • SARS-CoV-2

Substances

  • IFITM3 protein, human
  • Immunosuppressive Agents
  • Membrane Proteins
  • RNA-Binding Proteins
  • Interferons
  • Mycophenolic Acid